BRIUMVI® for Pregnancy Outcomes in Multiple Sclerosis
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- Age
- 15 – 50
- Sex
- Female
- Study type
- Observational
- Participants needed
- 728 (estimated)
- Sponsor
- TG Therapeutics, Inc. · Industry
This trial is looking for pregnant women with Multiple Sclerosis to compare birth outcomes between those who took BRIUMVI® and those who did not. Participants must have been pregnant recently or are currently pregnant.
You may be able to join if
- I have been diagnosed with Multiple Sclerosis
- I am currently pregnant or was pregnant within the last year
- I have received at least 1 dose of BRIUMVI® or have not taken it during my pregnancy
- I have permission from my healthcare provider to share my information
You may not be able to join if
- I have taken anti-CD20 monoclonal antibodies during my pregnancy
- I had my pregnancy outcome before my first contact with the research center
- I have been exposed to harmful substances or investigational medications during my pregnancy
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Loading trial locations…
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
1-877-411-4605
briumvipregnancyregistry@ppd.com
CONTACT